Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2.

The oncogene HER-2/neu encodes a transmembrane glycoprotein of 185 kDa (gp185HER-2) with tyrosine-kinase activity. Gene amplification and high levels of expression of gp185HER-2 have been found to correlate with poor clinical outcome in breast and ovarian carcinomas. Employing a somatic cell hybrid fusion protocol, which yields a high frequency production of hybridomas, we have analyzed the extent of the murine immune response to the gp 185 extracellular domain. In a single fusion experiment, using as immunogen NIH 3T3 cells expressing high levels of a transfected human HER-2 gene, we have generated mAbs, mainly of IgG1 isotype, displaying high affinity (10(7)-10(10) mol/L) to gp 185. Analysis of the epitope specificity has allowed the identification of five distinct groups of spatially related epitopes, each provided with different immunodominancy, and all resistant to formalin fixation. The use of inhibitor of N-linked glycosylation tunicamicyn has demonstrated that the mAbs bind to epitopes localized in the protein core of gp185HER-2. Because recent reports have shown that gp185HER-2 has a restricted expression in normal tissues and is homogenously detectable in metastatic foci of gp 185 + primary tumors, antibodies to this macromolecule, in addition to their prognostic value, may represent reagents for in vitro and in vivo diagnostic applications, as well as for the development of therapeutic strategies.

[1]  W. Carney,et al.  Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. , 1989, Oncogene.

[2]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.

[3]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[4]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[5]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.

[6]  W. Mahoney,et al.  Biological activities of the two major components of tunicamycin. , 1979, The Journal of biological chemistry.

[7]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[8]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[9]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[10]  M. Mariani,et al.  Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein. , 1987, Molecular immunology.

[11]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[12]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[13]  C. Molloy,et al.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency , 1991, Molecular and cellular biology.

[14]  S. Ferrone,et al.  Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. , 1983, Cancer research.

[15]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[16]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[17]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[18]  P. Natali,et al.  High frequency production of hybridomas secreting antibodies to cell antigens. , 1987, Hybridoma.

[19]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[20]  S. Singer,et al.  Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Berger,et al.  Expression of the c‐erbB‐2 protein in normal and transformed cells , 1987, International journal of cancer.

[23]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[24]  R. Weinberg,et al.  Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. , 1989, Cancer research.

[25]  R. Akita,et al.  An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. , 1991, Cancer research.